AFM Company Overview, Contact Details & Competitors

Q: What is AFM's official website and social media links?

AFM's official website is afmcollects.com. AFM has social profiles on LinkedIn.

Q: How many employees does AFM have currently?

AFM has approximately 76 employees.

Q: What technology does AFM use?

AFM's tech stack includes jQuery, Google Tag Manager, SOC 2, Webflow, Microsoft 365.

Q: What is AFM's NAICS code?

AFM's NAICS code is 52 (Finance and Insurance).

Insights

Gathering insights about AFM…

Similar companies to AFM

AFM Tech Stack

AFM uses 8 technology products and services including Rippling, Power BI, Cloudflare, and more. Explore AFM's tech stack below.

Rippling
Applicant Tracking Systems
Power BI
Business Intelligence
Cloudflare
Content Management System
Microsoft 365
Email
SOC 2
Governance, Risk And Compliance
SOC 1
Governance, Risk And Compliance
ISO/IEC 27001
Governance, Risk And Compliance
Google Cloud
Infrastructure As A Service

Media & News

Affimed Announces Receipt of Nasdaq Delisting Notice
MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company's common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 Notification of Delisting will be filed with the U.S. Securities Exchange Commission to delist the Company's securities from The Nasdaq Stock Market (“Nasdaq”).
May 14, 2025 | www.globenewswire.com
Affimed Announces Filing for the Opening of Insolvency Proceedings
MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany.
May 13, 2025 | www.globenewswire.com
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting
An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to improved objective response rate (33.3% vs 5.6%) and longer progression free survival (PFS) (7.3 mo. vs 2.9 mo.) without a negative impact on safetyThese findings will be incorporated in future AFM24 trials to further improve efficacy outcomes of patients treated with AFM24 MANNHEIM, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented findings on an exposure-outcome analysis of its innate cell engager (ICE®) AFM24, in patients with advanced or metastatic non-small cell lung cancer (NSCLC) in a poster session at the 2025 Annual Meeting of the American Association for Cancer Research (AACR). The analysis is based on post-hoc exposure-response data from 72 NSCLC patients treated with 480 mg of AFM24 monotherapy or a combination of AFM24 with atezolizumab. For all patients, trough levels over time were used to calculate the patient’s mean exposure to AFM24. Patients were then split into high and low AFM24 exposure groups for the analysis using the respective median as a cut-off. aAdsList.push('Article'); aAdsListSize.push([300, 250]); aAdsListCA.push(null); Key Findings from the Exposure-Response AnalysisObjective Response Rate (ORR): 33.3% in the high-exposure group vs. 5.6% in the low-exposure group (p=0.0059)Disease Control Rate (DCR): 83.3% vs. 58.3% (p=0.0367)Median Progression-Free Survival (mPFS): 7.33 vs. 2.86 monthsOverall Survival (OS): Not yet mature in the high-exposure group vs. 13 months in the low-exposure group A quartile analysis further confirmed the exposure-efficacy relationship, showing a stepwise increase in ORR from 0% in the lowest quartile to 50% in the highest. Subgroup analysis of 55 patients treated with AFM24 plus atezolizumab showed consistent results: 37.04% ORR in the high-exposure group vs. 7.14% in the low group. Importantly, higher exposure was not associated with an increased rate of more serious or severe adverse events. “Advanced NSCLC is a devastating disease and remains an area of high unmet need,” said Andreas Harstrick, MD, Chief Medical Officer of Affimed. “These findings strengthen our clinical rationale for dose optimization and highlight the potential of AFM24 – particularly in combination with atezolizumab – as a novel, chemotherapy-free, immunotherapy-based treatment approach. Importantly, the data suggest that achieving higher drug exposure early in treatment may prevent rapid disease progression.”Further Development Pharmacokinetic (PK) modeling indicates that a 720 mg weekly dose of AFM24—previously established as safe—achieves target exposure levels by the second week of treatment that correspond to the high exposure group in the post-hoc analysis. Based on these findings, Affimed will include the 720 mg dose moving forward to optimize clinical benefit and reduce early progression risk. “These data provide compelling evidence that higher exposure may translate to better outcomes in patients with advanced NSCLC,” Dr. Harstrick added. “With dose optimization in hand, we are positioned to advance AFM24 in its potential to deliver durable benefit in a difficult-to-treat patient population.”Conclusions The data show a strong correlation between exposure and clinical outcome with a significantly increased risk for early tumor progression in the low exposure group. PK modeling suggests that a dose of 720 mg AFM24 weekly will result in exposure levels exceeding the cutoff for the high exposure group as early as week two. The 720 mg dose, which has already been established as safe in the phase 1 trial, will be used in future AFM24 studies. More details about the programs for the AACR Annual Meeting 2025 are available online at AACR Annual Meeting 2025 | Meetings | AACR.About AFM24 AFM24 is a tetravalent, bispecific ICE® that activates the innate immune system by binding to CD16A on innate immune cells and epidermal growth factor receptors (EGFR), a protein widely expressed on solid tumors, to kill cancer cells. Generated by Affimed’s fit-for-purpose ROCK® platform, AFM24 represents a distinctive mechanism of action that uses EGFR as a docking site to engage innate immune cells for tumor cell killing through antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. About Affimed N.V. Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE®) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE® are generated on the Company’s proprietary ROCK® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com. Investor Relations Contact Alexander FudukidisDirector, Investor RelationsE-Mail: a.fudukidis@affimed.comTel.: +1 (917) 436-8102Media ContactMary Beth Sandin Vice President, Marketing and CommunicationsE-Mail: m.sandin@affimed.com Source: Affimed N.V.2025 GlobeNewswire, Inc., source Press Releases
Apr 29, 2025 | www.marketscreener.com
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting
MANNHEIM, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented findings on an exposure-outcome analysis of its innate cell engager (ICE®) AFM24, in patients with advanced or metastatic non-small cell lung cancer (NSCLC) in a poster session at the 2025 Annual Meeting of the American Association for Cancer Research (AACR).
Apr 29, 2025 | www.globenewswire.com
Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting
MANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on the phase 2 LuminICE-203 study of its innate cell engager (ICE®) acimtamig in combination with AlloNK® (AB-101) has been accepted for an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) taking place May 30 – June 3, 2025 in Chicago, Illinois. In addition, two abstracts on AFM24 in combination with atezolizumab in non-small cell lung cancer (NSCLC) have been accepted as poster presentations.
Apr 23, 2025 | www.globenewswire.com
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the “Notice”), dated April 15, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company's common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”).
Apr 21, 2025 | www.globenewswire.com
Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting
MANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on AFM24 dose optimization using exposure response analysis has been accepted for presentation as a poster at the Annual Meeting of the American Association for Cancer Research (AACR) taking place April 25-30, 2025 in Chicago, Illinois.
Mar 25, 2025 | www.globenewswire.com

AFM's Email Address Formats

AFM uses at least 2 format(s):

AFM Email Formats	Example	Percentage
FLast@afm-usa.com	JDoe@afm-usa.com	79%
FirstL@afm-usa.com	JohnD@afm-usa.com	8%
Last@afm-usa.com	Doe@afm-usa.com	8%
First@afm-usa.com	John@afm-usa.com	5%
First@afmcollects.com	John@afmcollects.com	100%

Frequently Asked Questions

Where is AFM's headquarters located?

AFM's main headquarters is located at 5500 Pearl Street Suite 250 Rosemont, Illinois 60018 United States. The company has employees across 5 continents, including North AmericaAsiaEurope.

What is AFM's stock symbol?

AFM is a publicly traded company; the company's stock symbol is AFMD.

What is AFM's official website and social media links?

AFM's official website is afmcollects.com and has social profiles on LinkedIn.

What is AFM's NAICS code?

AFM's NAICS code is 52 - Finance and Insurance.

How many employees does AFM have currently?

As of June 2026, AFM has approximately 76 employees across 5 continents, including North AmericaAsiaEurope. Key team members include Vice President Financial Operations: H. D.Senior Partner: W. P.Owner: S. D.. Explore AFM's employee directory with LeadIQ.

What industry does AFM belong to?

AFM operates in the Financial Services industry.

What technology does AFM use?

AFM's tech stack includes RipplingPower BICloudflareMicrosoft 365SOC 2SOC 1ISO/IEC 27001Google Cloud.

What is AFM's email format?

AFM's email format typically follows the pattern of FLast@afm-usa.com. Find more AFM email formats with LeadIQ.

When was AFM founded?

AFM was founded in 1981.

Insights

Similar companies to AFM

AMF

FCA

CVM

Bafin

MAS

Financial Industry Regulatory Authority (FINRA)

AFM Tech Stack

Media & News

Affimed Announces Receipt of Nasdaq Delisting Notice

Affimed Announces Filing for the Opening of Insolvency Proceedings

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting

AFM's Email Address Formats

Frequently Asked Questions

Where is AFM's headquarters located?

What is AFM's stock symbol?

What is AFM's official website and social media links?

What is AFM's NAICS code?

How many employees does AFM have currently?

What industry does AFM belong to?

What technology does AFM use?

What is AFM's email format?

When was AFM founded?

AFM

Company Overview

Media & News

Affimed Announces Receipt of Nasdaq Delisting Notice

Affimed Announces Filing for the Opening of Insolvency Proceedings

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?